Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.

Luo M, Chapel S, Sevinsky H, Savant I, Cirincione B, Bertz R, Roy A.

Antimicrob Agents Chemother. 2016 May 23;60(6):3676-86. doi: 10.1128/AAC.02678-15. Print 2016 Jun.

2.

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.

Larru B, Eby J, Lowenthal ED.

Pediatric Health Med Ther. 2014 May 29;5:29-42.

3.

Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study.

Mutwa PR, Boer KR, Asiimwe-Kateera B, Tuyishimire D, Muganga N, Lange JM, van de Wijgert J, Asiimwe A, Reiss P, Geelen SP.

PLoS One. 2014 Nov 3;9(11):e111948. doi: 10.1371/journal.pone.0111948. eCollection 2014.

4.

Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.

McIlleron HM, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry C, Smith P, Haas DW, Maartens G.

AIDS. 2013 Jul 31;27(12):1933-40.

5.

Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.

Salem AH, Fletcher CV, Brundage RC.

Antimicrob Agents Chemother. 2014;58(1):136-43. doi: 10.1128/AAC.01738-13. Epub 2013 Oct 21.

6.

Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008).

Álvaro-Meca A, Jensen J, Micheloud D, Díaz A, Gurbindo D, Resino S.

BMC Infect Dis. 2013 Mar 4;13:115. doi: 10.1186/1471-2334-13-115.

7.

Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.

van Dijk JH, Sutcliffe CG, Hamangaba F, Bositis C, Watson DC, Moss WJ.

PLoS One. 2013;8(1):e55111. doi: 10.1371/journal.pone.0055111. Epub 2013 Jan 25.

8.

Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.

Beck IA, Jang M, McKernan-Mullin J, Bull M, Wagner T, Huang S, Song LY, Nachman S, Krogstad P, Eshleman SH, Wiznia A, Frenkel LM.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):780-8. doi: 10.1089/AID.2011.0039. Epub 2012 Jan 27.

9.

Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy.

Prabhakar B, Banu A, Pavithra HB, Chandrashekhara P, Sasthri S.

Indian J Sex Transm Dis. 2011 Jul;32(2):94-8. doi: 10.4103/0253-7184.85412.

10.

Induction maintenance concept for HAART as initial treatment in HIV infected infants.

Ghosh S, Neubert J, Niehues T, Adams O, Morali-Karzei N, Borkhardt A, Laws HJ.

Eur J Med Res. 2011 Jun 21;16(6):243-8.

11.

Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

Ahoua L, Guenther G, Rouzioux C, Pinoges L, Anguzu P, Taburet AM, Balkan S, Olson DM, Olaro C, Pujades-Rodríguez M.

BMC Pediatr. 2011 Jul 26;11:67. doi: 10.1186/1471-2431-11-67.

12.

Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.

King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP; P1058 Protocol Team.

Antimicrob Agents Chemother. 2011 Sep;55(9):4290-4. doi: 10.1128/AAC.01334-10. Epub 2011 Jun 13.

13.

HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy.

van Dijk JH, Sutcliffe CG, Munsanje B, Sinywimaanzi P, Hamangaba F, Thuma PE, Moss WJ.

PLoS One. 2011 Apr 28;6(4):e19006. doi: 10.1371/journal.pone.0019006.

14.

Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries.

Peacock-Villada E, Richardson BA, John-Stewart GC.

Pediatrics. 2011 Feb;127(2):e423-41. doi: 10.1542/peds.2009-2701. Epub 2011 Jan 24. Review.

15.

Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells.

Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia A, Esplugues JV.

Br J Pharmacol. 2010 Aug;160(8):2069-84. doi: 10.1111/j.1476-5381.2010.00866.x.

16.

Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study.

Emmett SD, Cunningham CK, Mmbaga BT, Kinabo GD, Schimana W, Swai ME, Bartlett JA, Crump JA, Reddy EA.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):368-75. doi: 10.1097/QAI.0b013e3181cf4882.

17.

Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.

Reitz C, Coovadia A, Ko S, Meyers T, Strehlau R, Sherman G, Kuhn L, Abrams EJ.

J Infect Dis. 2010 Apr 15;201(8):1121-31. doi: 10.1086/651454.

18.

Pharmacotherapy of pediatric and adolescent HIV infection.

Schuval SJ.

Ther Clin Risk Manag. 2009 Jun;5(3):469-84. Epub 2009 Jun 22.

19.

Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?

Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S, Zoure E, Rouet F, Hien H, Msellati P, Van De Perre P, Tréluyer JM.

Antimicrob Agents Chemother. 2009 Oct;53(10):4407-13. doi: 10.1128/AAC.01594-08. Epub 2009 Jul 27.

20.

Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa.

Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, Cotton M, Maartens G.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):65-71. doi: 10.1097/QAI.0b013e318199072e.

Items per page

Supplemental Content

Write to the Help Desk